Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q2 2026 › vs Q2 2025
Amphastar Pharmaceuticals (AMPH) Q2 2026 vs Q2 2025 (year over year)
Amphastar Pharmaceuticals's revenue rose $9.5M (+5%) from $174M in Q2 2025 to $184M in Q2 2026. Gross margin 50.8% against 49.6% (+1.2 pts).
Amphastar Pharmaceuticals, Q2 2026: revenue $184M (+5% year over year), operating margin 21.6%, net earnings $30.3M, operating cash flow $51.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 50.8% | 49.6% | +1.2 pts |
| Operating margin | 21.6% | 24.2% | -2.6 pts |
| Net margin | 16.5% | 17.8% | -1.3 pts |
| Free cash flow margin | 23.2% | 14.3% | +8.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $184M | $174M | $9.5M | +5% |
| Gross profit | $93.5M | $86.5M | $7.0M | +8% |
| Cost of revenue | $90.4M | $87.9M | $2.5M | +3% |
| Operating profit | $39.7M | $42.2M | −$2.5M | -6% |
| Operating expenses | $53.7M | $44.3M | $9.4M | +21% |
| Pre-tax earnings | $38.5M | $39.3M | −$791K | -2% |
| Other expense, net | $1.2M | $2.8M | −$1.7M | -58% |
| Research & development | $22.2M | $20.1M | $2.1M | +10% |
| Sales & marketing | $13.3M | $10.2M | $3.1M | +30% |
| General & admin | $18.2M | $14.0M | $4.3M | +30% |
| Net earnings | $30.3M | $31.0M | −$682K | -2% |
| Income tax | $8.2M | $8.3M | −$109K | -1% |
| Depreciation & amortization | $14.3M | $14.6M | −$305K | -2% |
| Share-based compensation | $7.1M | $6.4M | $708K | +11% |
| Working capital & other | $425K | $16.4M | −$16.0M | -97% |
| Operating cash flow | $51.3M | $35.6M | $15.7M | +44% |
| Free cash flow (OCF − capex) | $42.7M | $25.0M | $17.7M | +71% |
| Capital expenditures | $8.6M | $10.6M | −$2.0M | -19% |
Questions
How much did Amphastar Pharmaceuticals's revenue grow year over year in Q2 2026?
Amphastar Pharmaceuticals's revenue rose $9.5M (+5%) from $174M in Q2 2025 to $184M in Q2 2026. Gross margin 50.8% against 49.6% (+1.2 pts).